

# Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women<sup>1</sup>

Rebecca L. Sedjo, Paula Inserra, Martha Abrahamsen, Robin B. Harris, Denise J. Roe, Susie Baldwin, and Anna R. Giuliano<sup>2</sup>

Arizona Cancer Center [R. L. S., M. A., R. B. H., D. J. R., S. B., A. R. G.], Arizona College of Public Health [R. B. H., D. J. R., A. R. G.], and Obstetrics and Gynecology [S. B.], University of Arizona, Tucson, Arizona 85724-5024, and Stanley S. Scott Cancer Center, Louisiana State University Health Science Center, New Orleans, Louisiana 70112 [P. I.]

## Abstract

**Persistent oncogenic human papillomavirus (HPV) infection is associated with cervical dysplasia. Cofactors, such as nutrient status, may be required for the progression of HPV infection to neoplasia. HPV DNA methylation patterns *in vitro* have been shown to be associated with viral transcriptional activity. Folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine may function to prevent cervical cancer through their role in DNA methylation. This study was conducted to examine the relationship of dietary intake of folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine, as well as circulating levels of folate and vitamin B<sub>12</sub> to HPV persistence. Oncogenic HPV status was determined at baseline and at ~3 and 9 months postbaseline. Multivariate logistic regression analysis was used to determine the adjusted odds ratios for persistent HPV infection associated with each tertile of individual nutrient among 201 women with a persistent or intermittent HPV infection. Circulating vitamin B<sub>12</sub> levels were inversely associated with HPV persistence (*P* for trend, 0.037) after adjusting for age, age at first intercourse, marital status, cigarette smoking status, race, and body mass index. In addition, women with circulating levels in the highest tertile (>493.2 pg/ml) of vitamin B<sub>12</sub> were less likely to have a persistent infection (adjusted odds ratio = 0.4; 95% confidence interval = 0.17–0.96). No significant associations were observed between HPV persistence and dietary intake of folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, or methionine from food alone or from food and supplements combined or from circulating folate. These data suggest a role for circulating vitamin B<sub>12</sub> in early cervical carcinogenesis.**

Received 8/24/01; revised 1/11/02; accepted 1/23/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported in part by Arizona Disease Control Research Commission grants (contracts 9710 and 10004). Dr. Sedjo was supported by a National Cancer Institute Pre-Doctoral Cancer Prevention Fellowship (R25-CA78447). Dr. Giuliano was supported in part by a National Cancer Institute Career Development Award (K07-CA60885).

<sup>2</sup> To whom requests for reprints should be addressed, at Arizona Cancer Center, 1515 N. Campbell Avenue, Room 4977 C, Tucson, AZ 85724-5024. Phone: (520) 626-3341; Fax: (520) 626-3343; E-mail: agiuliano@azcc.arizona.edu.

## Introduction

Cervical cancer is the third leading cause of cancer in women, comprising 9.8% of new cancer cases worldwide (1). Infection with oncogenic HPVs<sup>3</sup> has been shown to be the primary etiological factor for cervical cancer (2–4), as well as its precursor lesion, cervical intraepithelial neoplasia (5–7). HPV infections are often transient (8, 9), but persistent infections, especially with oncogenic HPV types, can further increase the risk of cervical dysplasia (5, 6, 10, 11). Although HPV infection is essential for cervical cancer, not all women infected with the virus progress to invasive cervical cancer. Nutritional factors may contribute to the progression of HPV infection to neoplasia (12).

*In vitro* evidence indicates that HPV DNA methylation patterns are associated with viral transcriptional activity (13). Methylation of the upstream regulatory region of HPV has been shown to prevent transcription *in vitro*, suggesting that methylation can decrease viral proliferation (14). Folate, as well as vitamins B<sub>12</sub> and B<sub>6</sub>, may function to prevent cervical cancer through their role in DNA methylation as they contribute to the synthesis of S-adenosylmethionine (15, 16), the primary donor for the methylation of DNA and RNA (17).

Despite compelling biochemical evidence for a role of folate and vitamin B<sub>12</sub>, the epidemiological literature has not supported an association with cervical neoplasia. Case control studies assessing dietary folate intake have not shown a protective effect against cervical dysplasia (18–21), carcinoma *in situ* (22, 23), or invasive cervical cancer (24–26).

Furthermore, of the five case control studies that assessed the association between cervical dysplasia and circulating folate concentrations (18, 20, 27–29), only two reported a protective effect (18, 27). Similarly, higher circulating concentrations of folate were not protective against invasive cervical cancer (30–32). Two investigations assessed circulating vitamin B<sub>12</sub> levels, but neither observed an association between cervical dysplasia (28) and cancer (30). Finally, three clinic trials of folic acid supplementation were conducted among women with cervical dysplasia (33–35). Only one of these trials resulted in cytological improvement (33).

As the majority of epidemiological studies that assessed the association between methyl donor nutrients and risk of cervical neoplasia did not include measures of HPV status, these studies must be interpreted with caution. No previous investigation has evaluated the association between folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine and the early carcinogenic event of HPV persistence. Therefore, this study was conducted to test whether increased dietary intake of folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, or methionine, or circulating levels of

<sup>3</sup> The abbreviations used are: HPV, human papillomavirus; RLU, relative light unit; AFFQ, Arizona Food Frequency Questionnaire; USDA, United States Dietary Association; BMI, body mass index; CI, confidence interval; OR, odds ratio.

folate or vitamin B<sub>12</sub>, are associated with decreased risk of HPV persistence.

### Materials and Methods

The Young Women's Health Study was a prospective cohort study designed to investigate the natural history of HPV infections among healthy women. Study visits occurred at baseline and ~3- and 9-months postbaseline. The University of Arizona's Human Subjects Committee approved this study protocol. Before study entry, all participants signed an informed consent form.

**Subjects.** From September 1996 to August 1999, all healthy women receiving routine gynecological care at a reproductive health care clinic were approached by a study interviewer for participation in the Young Women's Health Study. Of the 1950 women approached, 1541 women met the eligibility criteria, and 1342 women were enrolled in the baseline visit. Eligibility criteria included being aged 18–35 years, currently sexually active or seeking birth control, resident of the Tucson metropolitan area, no treatment for cervical intraepithelial neoplasia within the last 18 months, no abnormal Pap smear in the last 18 months, no history of chronic illness, not currently pregnant and >2 months postpartum, still having menstrual periods (*i.e.*, no hysterectomy), and no relocation plans over the next 12 months. At the baseline visit, each participant completed an extensive self-administered questionnaire regarding socio-demographics, cigarette smoking history, sexual behaviors, and reproductive history. During each participant's routine gynecological examination, exfoliated cells for HPV analysis were collected after Pap smear sample collection.

A group of 822 women (61%) who completed the baseline visit and had a baseline Pap smear of negative or atypical squamous cells of undetermined significance were invited to participate in the follow-up visits. Women, who were positive for any one of 13 oncogenic HPV types or HPV negative at baseline, were recruited to the follow-up visits. Women who were HPV negative were included in the study as they were at risk for acquiring an HPV infection over the study period. Groups of 346 and 206 women completed scheduled 3- and 9-month study visits, respectively. Of the 346 women who completed at least one follow-up visit, 187 (54%) were positive for an oncogenic HPV infection at baseline, and the remaining were HPV negative. Cytology and HPV testing were performed as part of each follow-up gynecological examination. Participants were monetarily compensated (\$50) for participation in each of the follow-up visits. Women completing follow-up visits were more educated ( $P = 0.05$ ) and less likely to be current smokers ( $P < 0.01$ ) than women completing the baseline visit only; however, there were no significant differences in age, race, marital status, age at first intercourse, number of sexual partners, parity, oral contraceptive use, and ever having a Pap smear (data not shown).

**HPV Analysis.** HPV status at the baseline and follow-up visits was determined using Hybrid Capture II (Digene Corp, Beltsville, MD) to detect oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Positive samples were defined as a ratio of greater than 1 RLU of sample divided by RLUs of a positive control. Repeat testing was conducted on samples with equivocal readings (range 1–2 RLUs) with results of  $\geq 1$  RLU classified as positive. Samples with repeated values  $< 1$  RLU were analyzed a third time and classified based on the results of the two concordant results. Approximately, 1 pg of viral DNA/ml sample can be detected by this method (36).

Because the objectives of this investigation were to test the

association of nutrients involved in methylation with HPV persistence, only participants who tested positive for an HPV infection and had at least one follow-up visit were included in this analysis. HPV persistence was defined as women who were HPV positive for any oncogenic HPV infection at two or more consecutive time points ( $n = 131$ ), whereas women who were positive for any oncogenic type infection at one or more non-consecutive time points were classified as having intermittent infections ( $n = 70$ ). Women who tested negative for HPV until the last clinic visit, and then tested positive ( $n = 24$ ), and women who were consistently HPV negative ( $n = 121$ ) were excluded from these analyses.

**Dietary Intake Analysis.** Trained interviewers administered the AFFQ at the 3-month visit. The AFFQ is a modification of the dietary portion of the Block National Cancer Institute Health Habits and History Questionnaire (37) and includes foods common to the Southwestern United States (*i.e.*, salsa and burritos), as well as low-fat food items. Vitamin supplement duration, dosage, and brand are included. This optically scannable, semiquantitative questionnaire measured participants' usual intake by asking questions regarding the frequency and portion size of 153 food items over the previous 3 months. The validity and reliability of this questionnaire have been investigated through comparisons with four 24-h food recalls, as well as repeated administration after 1 year of both AFFQ and four 24-h recalls (38) or four dietary records (39) in two different prospective studies.

Nutrient values were calculated from the participants' reported dietary and supplement intake using a database derived from the 1994 USDA Food Composition Database, the USDA Continuing Survey of Food Intake of Individuals 1994–1996 and 1998, and the Nutrient Database for Standard Reference (version 11–13). To capture the additional folate intake because of fortification of enriched grain products, mandated by the United States Food and Drug Administration as of January 1, 1998 (40), two databases were used. Questionnaires completed on or after January 1, 1998 were analyzed from the database, which included fortified grain products, whereas questionnaires completed before this date were analyzed without the updated fortification values. A group of 140 participants completed the AFFQ before January 1, 1998, and 206 participants completed the AFFQ after this date. All dietary calculations used age-specific portion sizes for women. From these databases, semiquantitative nutrient intake values were obtained for folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine.

**Circulating Folate and Vitamin B<sub>12</sub> Measures.** At the 3- and 9-month clinic visits, fasting blood samples were collected by venipuncture using Monoject evacuated tubes containing EDTA (Sherwood Medical, St. Louis, MO) for quantitative assessment of circulating nutrient values. All samples were separated, and the resulting plasma aliquots were stored at  $-80^{\circ}\text{C}$  until analyses were conducted.

Plasma samples were obtained from 285 participants, 82% who completed the 3-month study visit, and 180 participants, 87% who completed the 9-month study visit. Twenty women completed both the 3- and 9-month visits, but blood was obtained only at the 9-month visit. The most common reasons for not obtaining blood ( $n = 41$ ) were that the phlebotomist was unable to find a vein ( $n = 29$ ), only a small amount of blood was obtained ( $n = 8$ ), or the participant refused ( $n = 4$ ). Participants with and without samples were comparable on age, race, education, marital status, cigarette smoking, and BMI.

Plasma folate and vitamin B<sub>12</sub> were quantified in duplicate using the Quantaphase II B<sub>12</sub> and Folate Radioassay (Bio-Rad

Table 1 Unadjusted mean<sup>a</sup> values of dietary intake and circulating nutrient levels by case control status

|  | Intermittent HPV infection |         | Persistent HPV infection |         | P    |
|--|----------------------------|---------|--------------------------|---------|------|
|  | Mean                       | (SD)    | Mean                     | (SD)    |      |
| Dietary Intake of Micronutrients             |                            |         |                          |         |      |
| Foods Only <sup>b</sup>                      |                            |         |                          |         |      |
| Folate ( $\mu\text{g}$ )                     | 453.3                      | (330.7) | 396.3                    | (220.4) | 0.51 |
| Vitamin B <sub>12</sub> ( $\mu\text{g}$ )    | 4.9                        | (3.2)   | 4.6                      | (2.7)   | 0.85 |
| Vitamin B <sub>6</sub> (mg)                  | 2.4                        | (1.4)   | 2.1                      | (1.1)   | 0.48 |
| Methionine (gm)                              | 1.7                        | (1.1)   | 1.7                      | (0.9)   | 0.81 |
| Food and Supplements Combined <sup>c</sup>   |                            |         |                          |         |      |
| Folate ( $\mu\text{g}$ )                     | 626.6                      | (420.3) | 578.6                    | (346.7) | 0.54 |
| Vitamin B <sub>12</sub> ( $\mu\text{g}$ )    | 12.0                       | (16.1)  | 15.8                     | (52.5)  | 0.68 |
| Vitamin B <sub>6</sub> (mg)                  | 5.4                        | (7.5)   | 5.6                      | (9.1)   | 0.60 |
| Plasma Levels                                |                            |         |                          |         |      |
| Folate (ng/ml) <sup>d</sup>                  | 7.9                        | (3.3)   | 8.8                      | (3.7)   | 0.16 |
| Vitamin B <sub>12</sub> (pg/ml) <sup>e</sup> | 439.8                      | (159.5) | 405.5                    | (176.8) | 0.10 |

<sup>a</sup> Means are presented as untransformed values but were calculated from log-transformed values.

<sup>b</sup> Intermittent = 70, Persistent = 131.

<sup>c</sup> Intermittent = 70 with 34 consuming supplements, Persistent = 131 with 66 consuming supplements.

<sup>d</sup> Intermittent = 60, Persistent = 109.

<sup>e</sup> Intermittent = 60, Persistent = 110.

Laboratories, Inc., Hercules, CA). To minimize interference because of EDTA, plasma samples were filtered using serum filter columns (Image Molding, Denver, CO) before analysis. On the basis of repeated measurements of a pooled plasma sample, the interassay coefficient of variation was 13% for plasma folate and 0.41% for plasma vitamin B<sub>12</sub>.

The average of two plasma values was used unless only one sample was available, in which case, the single value was used. Overall, 60 (86%) participants with intermittent infections and 109 (83%) participants with persistent infections had available plasma samples for analysis. The Pearson correlation coefficients of log-transformed 3- and 9-month nutrient levels were significant at  $r = 0.45$  ( $P < 0.01$ ) for folate and  $r = 0.42$  ( $P < 0.01$ ) for vitamin B<sub>12</sub> among participants with both measures. Although at least one plasma sample was available for 298 participants, only participants who had an intermittent or persistent HPV infection were included in the statistical analyses ( $n = 170$ ). Because of a single inadequate sample, 169 participants had samples available for folate analysis.

**Statistical Analysis.** To test whether increased dietary intake levels of nutrients involved in the methylation pathway were associated with decreased HPV persistence, two groups were compared: women with persistent infections ( $n = 131$ ) and women with intermittent infections ( $n = 70$ ). Nutrient intake and plasma levels were categorized into tertiles based on the distribution of the intermittent group. Bivariate analyses were conducted for age, race, education, marital status, cigarette smoking history, age at first intercourse, lifetime number of sexual partners, parity, number of pregnancies, oral contraceptive use, Depo Provera use, and Pap smear history, as well as variables that would account for under and over-reporting of dietary intake, such as BMI and total energy intake.  $\chi^2$  analyses for categorical variables and two sample  $t$  tests or ANOVAs for continuous variables were used. Non-nutrient risk factors associated with both HPV persistence and any dietary or plasma nutrient at  $P \leq 0.2$  were assessed in multivariate logistic regression models. To maximize statistical power, only those variables associated with both nutrient status and HPV persistence were retained as covariates using multivariate analysis. Backwards stepwise elimination was performed, and only significant variables at  $P < 0.05$  (age at first intercourse, marital status, race, and BMI) were retained in the final model. Age and

cigarette smoking ( $P = 0.052$ ) were also included in the model to be consistent with the literature. Because of the high inter-correlation of the nutrients, risk of HPV persistence was estimated individually for each nutrient. Multivariate logistic regression modeling of HPV persistence was performed to obtain an estimate of the association (adjusted OR) and 95% CIs. Treating categorical nutrient variables as continuous variables in multivariate logistic regression allowed for the assessment of linear trends. Pearson correlation coefficients were estimated between circulating and dietary nutrient levels using the log-transformed values as these data were highly skewed. All statistical tests performed were two sided with an  $\alpha$  level of 0.05 and were performed using Intercooled STATA (2001 Stata Statistical Software: Release 7.0; StataCorp., College Station, TX).

## Results

The unadjusted mean values of dietary intake and circulating nutrient levels for participants with intermittent and persistent HPV infections are reported in Table 1. No significant differences were observed in dietary intake from food alone or food and supplements combined for folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine among participants with persistent HPV infections and participants with intermittent HPV infections. Circulating folate and vitamin B<sub>12</sub> levels were equivalent when participants with persistent and intermittent HPV infections were compared.

Dietary folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine intakes from food sources were highly intercorrelated, *e.g.*, a correlation coefficient of  $r = 0.92$  ( $P < 0.01$ ) was observed between dietary folate and vitamin B<sub>6</sub>. The high correlation coefficients were likely because of fortification of these nutrients simultaneously in certain foods, such as fortified breakfast cereals, which were reported frequently by study participants. In this cohort, the correlations between dietary nutrients from foods and circulating folate and vitamin B<sub>12</sub> concentrations were low;  $r = 0.10$  ( $P = 0.21$ ) for folate and  $r = 0.15$  ( $P = 0.18$ ) for vitamin B<sub>12</sub>. Eighty-three (41%) women consumed vitamin supplements of folate, vitamin B<sub>6</sub>, and B<sub>12</sub>. The correlations between dietary nutrients and their plasma concentrations remained low when nutrients from supplements were

Table 2 Distribution of socio-demographic and cervical neoplasia risk factor characteristics by tertiles of dietary intake and circulating measures among study participants

| Tertiles   | Dietary food intake                 |            |                          |  |            |                          |                |             |            | Plasma levels                   |            |                   |  |  |  |  |  |  |
|--|-------------------------------------|------------|--------------------------|--|------------|--------------------------|----------------|-------------|------------|---------------------------------|------------|-------------------|--|--|--|--|--|--|
|  | Folate ( $\mu\text{g}/\text{day}$ ) |            |                          | Vitamin B <sub>12</sub> ( $\mu\text{g}/\text{day}$ ) |            |                          | Folate (ng/ml) |             |            | Vitamin B <sub>12</sub> (pg/ml) |            |                   |  |  |  |  |  |  |
|  | 1                                   | 2          | 3                        | 1  | 2          | 3                        | 1              | 2           | 3          | 1                               | 2          | 3                 |  |  |  |  |  |  |
| No.  | 77                                  | 66         | 58                       | 65   | 78         | 58                       | 50             | 52          | 67         | 74                              | 51         | 45                |  |  |  |  |  |  |
| Age (yr), mean (SD) <sup>a</sup>                               | 24 (4)                              | 25 (4)     | 23 (4)                   | 24 (4)   | 24 (4)     | 23 (4)                   | 23 (4)         | 25 (5)      | 24 (5)     | 25 (4)                          | 24 (5)     | 23 (5)            |  |  |  |  |  |  |
| Race (%) <sup>b</sup>  |                                     |            |                          |  |            |                          |                |             |            |                                 |            |                   |  |  |  |  |  |  |
| Caucasian  | 85.7                                | 84.9       | 65.5                     | 86.2   | 79.5       | 72.4                     | 72.0           | 84.6        | 80.6       | 87.8                            | 68.6       | 77.8              |  |  |  |  |  |  |
| Hispanic   | 9.1                                 | 10.6       | 29.3                     | 7.7  | 16.7       | 22.4                     | 22.0           | 11.5        | 16.4       | 9.5                             | 23.5       | 20.0              |  |  |  |  |  |  |
| Other  | 5.2                                 | 4.6        | 5.1 <sup>c</sup>         | 6.2  | 3.9        | 5.2                      | 6.0            | 3.9         | 3.0        | 2.7                             | 7.8        | 2.2 <sup>c</sup>  |  |  |  |  |  |  |
| Education (% $\geq$ some college) <sup>b</sup>                 | 70.1                                | 68.2       | 77.6                     | 73.9   | 71.8       | 69.0                     | 66.0           | 67.3        | 77.6       | 74.3                            | 29.4       | 33.3              |  |  |  |  |  |  |
| Marital status (%) <sup>b</sup>                                |                                     |            |                          |  |            |                          |                |             |            |                                 |            |                   |  |  |  |  |  |  |
| Single   | 64.9                                | 72.7       | 74.1                     | 64.6   | 74.4       | 70.7                     | 60.0           | 67.3        | 73.1       | 66.2                            | 70.6       | 66.7              |  |  |  |  |  |  |
| Married  | 11.7                                | 7.6        | 5.2                      | 10.8   | 11.5       | 1.7                      | 14.0           | 7.7         | 4.5        | 10.8                            | 5.9        | 6.7               |  |  |  |  |  |  |
| Cohabiting   | 7.8                                 | 12.1       | 15.5                     | 10.8   | 7.7        | 17.2                     | 14.0           | 13.5        | 11.9       | 14.9                            | 13.7       | 8.9               |  |  |  |  |  |  |
| Divorced/separated   | 15.6                                | 7.6        | 5.2                      | 13.9   | 6.4        | 10.3                     | 12.0           | 11.5        | 10.5       | 8.1                             | 9.8        | 17.8              |  |  |  |  |  |  |
| BMI, mean (SD) <sup>a</sup>                                    | 23.8 (5.5)                          | 23.6 (5.2) | 22.8 (4.5)               | 23.5 (5.2)   | 23.6 (5.1) | 23.1 (5.3)               | 24.3 (6.1)     | 23.3 (4.2)  | 22.9 (5.6) | 23.3 (5.1)                      | 24.0 (6.4) | 23.1 (4.5)        |  |  |  |  |  |  |
| Total energy (kcal), mean (SD) <sup>a</sup>                    | 1221 (531)                          | 2127 (717) | 3095 <sup>c</sup> (1278) | 1248 (624)   | 1933 (704) | 3138 <sup>c</sup> (1257) | 2322 (1312)    | 2091 (1401) | 1879 (856) | 2041 (956)                      | 1959 (983) | 224 (1668)        |  |  |  |  |  |  |
| Cigarette smoking (% ever) <sup>b</sup>                        | 48.1                                | 50.0       | 55.2                     | 52.3   | 43.6       | 58.6                     | 48.0           | 55.8        | 53.7       | 54.1                            | 51.0       | 53.3              |  |  |  |  |  |  |
| Age @ 1 <sup>st</sup> intercourse (yr), mean (SD) <sup>a</sup> | 17 (3)                              | 17 (3)     | 17 (2)                   | 17 (3)   | 17 (3)     | 16 (2)                   | 17 (2)         | 17 (4)      | 16 (2)     | 17 (3)                          | 17 (4)     | 16 (2)            |  |  |  |  |  |  |
| Lifetime # sexual partners, mean (SD) <sup>a</sup>             | 9 (8)                               | 10 (10)    | 9 (7)                    | 10 (9)   | 9 (8)      | 10 (9)                   | 8 (9)          | 11 (11)     | 10 (7)     | 11 (9)                          | 9 (11)     | 9 (7)             |  |  |  |  |  |  |
| Parity (% ever) <sup>b</sup>                                   | 27.3                                | 21.2       | 13.8                     | 30.7   | 15.4       | 19.0                     | 28.0           | 30.8        | 15.0       | 23.0                            | 23.5       | 24.4              |  |  |  |  |  |  |
| Oral contraceptive use (%) <sup>b</sup>                        |                                     |            |                          |  |            |                          |                |             |            |                                 |            |                   |  |  |  |  |  |  |
| Never  | 14.3                                | 10.6       | 19.0                     | 16.9   | 6.4        | 22.4                     | 22.0           | 11.5        | 7.5        | 9.5                             | 13.7       | 17.8              |  |  |  |  |  |  |
| Current  | 47.8                                | 36.4       | 39.7                     | 47.7   | 41.0       | 34.5                     | 42.0           | 46.2        | 41.8       | 56.8                            | 43.1       | 20.0              |  |  |  |  |  |  |
| Past   | 39.0                                | 53.0       | 41.4                     | 35.3   | 52.6       | 43.1                     | 36.0           | 42.3        | 50.8       | 33.8                            | 43.1       | 62.2 <sup>c</sup> |  |  |  |  |  |  |

<sup>a</sup> Analysis of covariance.

<sup>b</sup> Pearson  $\chi^2$  test of association.

<sup>c</sup>  $P < 0.05$ .

**Table 3** Association between specific dietary micronutrient intake and HPV persistence,  $n = 201$ 

|  | Intermittent No. | Persistent No. | Crude OR | Adjusted OR (95% CI) |
|--|------------------|----------------|----------|----------------------|
| <b>Food only</b>   |                  |                |          |                      |
| <b>Folate (<math>\mu\text{g}</math>)</b>                 |                  |                |          |                      |
| Low (<301.6)   | 24               | 53             | 1.00     | 1.00                 |
| Medium (301.6–481.6)                                     | 23               | 43             | 0.85     | 0.63 (0.29–1.38)     |
| High (>481.6)  | 23               | 35             | 0.69     | 0.52 (0.23–1.18)     |
| <i>P</i> for trend                                       |                  |                |          | 0.109                |
| <b>Vitamin B<sub>12</sub> (<math>\mu\text{g}</math>)</b> |                  |                |          |                      |
| Low (<2.9)   | 24               | 41             | 1.00     | 1.00                 |
| Medium (2.9–6.0)   | 23               | 55             | 1.40     | 1.47 (0.68–3.19)     |
| High (>6.0)  | 23               | 35             | 0.89     | 0.68 (0.30–1.54)     |
| <i>P</i> for trend                                       |                  |                |          | 0.439                |
| <b>Vitamin B<sub>6</sub> (mg)</b>                        |                  |                |          |                      |
| Low (<1.6)   | 24               | 44             | 1.00     | 1.00                 |
| Medium (1.6–2.7)   | 23               | 53             | 1.26     | 0.92 (0.43–2.00)     |
| High (>2.7)  | 23               | 34             | 0.81     | 0.61 (0.27–1.39)     |
| <i>P</i> for trend                                       |                  |                |          | 0.254                |
| <b>Methionine (grams)</b>                                |                  |                |          |                      |
| Low (<1.2)   | 24               | 34             | 1.00     | 1.00                 |
| Medium (1.2–1.9)   | 23               | 55             | 1.69     | 1.29 (0.58–2.86)     |
| High (>1.9)  | 23               | 42             | 1.29     | 1.25 (0.56–2.80)     |
| <i>P</i> for trend                                       |                  |                |          | 0.590                |
| <b>Food + supplements combined</b>                       |                  |                |          |                      |
| <b>Folate (<math>\mu\text{g}</math>)</b>                 |                  |                |          |                      |
| Low (<301.6)   | 24               | 49             | 1.00     | 1.00                 |
| Medium (301.6–481.6)                                     | 23               | 33             | 0.70     | 0.80 (0.38–1.69)     |
| High (>481.6)  | 23               | 49             | 1.05     | 1.16 (0.56–2.39)     |
| <i>P</i> for trend                                       |                  |                |          | 0.686                |
| <b>Vitamin B<sub>12</sub> (<math>\mu\text{g}</math>)</b> |                  |                |          |                      |
| Low (<2.9)   | 24               | 48             | 1.00     | 1.00                 |
| Medium (2.9–6.0)   | 23               | 46             | 1.00     | 1.11 (0.53–2.31)     |
| High (>6.0)  | 23               | 37             | 0.80     | 0.96 (0.46–2.03)     |
| <i>P</i> for trend                                       |                  |                |          | 0.933                |
| <b>Vitamin B<sub>6</sub> (mg)</b>                        |                  |                |          |                      |
| Low (<2.32)  | 24               | 51             | 1.00     | 1.00                 |
| Medium (2.32–4.18)                                       | 23               | 45             | 0.92     | 1.03 (0.50–2.13)     |
| High (>4.18)   | 23               | 35             | 0.72     | 0.83 (0.39–1.79)     |
| <i>P</i> for trend                                       |                  |                |          | 0.647                |

<sup>a</sup> Adjusted for age, age at first intercourse, marital status, cigarette smoking status, race, and BMI.

combined with food values;  $r = 0.23$  ( $P < 0.01$ ) for folate and  $r = 0.26$  ( $P < 0.01$ ) for vitamin B<sub>12</sub>.

The distributions of socio-demographic and cervical neoplasia risk factor characteristics by tertiles of dietary food intake and circulating measures are reported in Table 2. Race was significantly associated with dietary folate intake from food and circulating vitamin B<sub>12</sub> concentrations, and energy was associated with both food folate and vitamin B<sub>12</sub> intake. The oral contraceptive used was significantly associated with circulating vitamin B<sub>12</sub> concentrations.

Table 3 presents the association between specific dietary nutrients and HPV persistence. No significant associations were observed between HPV persistence and dietary folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine. Furthermore, no association was observed with HPV persistence when combined measures of food and supplement intake for folate, vitamin B<sub>6</sub>, or vitamin B<sub>12</sub> were examined. Although not statistically significant, an inverse association was observed between dietary folate from food alone and HPV persistence. Among women consuming the highest level of folate from food sources, risk of HPV persistence was 0.52 (95% CI = 0.23–1.18).

Table 4 presents the association between circulating nu-

**Table 4** Association between circulating nutrients and HPV persistence

|   | Intermittent No. | Persistent No. | Crude OR | Adjusted OR ("95% CI) |
|---|------------------|----------------|----------|-----------------------|
| <b>Folate (<math>\mu\text{g/ml}</math>)<sup>b</sup></b> |                  |                |          |                       |
| Low (<6.48)   | 20               | 30             | 1.00     | 1.00                  |
| Medium (6.48–8.80)                                      | 20               | 32             | 1.07     | 0.95 (0.39–2.29)      |
| High (>8.80)  | 20               | 47             | 1.57     | 1.20 (0.51–2.78)      |
| <i>P</i> for trend                                      |                  |                |          | 0.662                 |
| <b>Vitamin B<sub>12</sub> (pg/ml)<sup>c</sup></b>       |                  |                |          |                       |
| Low (<357.7)  | 20               | 54             | 1.00     | 1.00                  |
| Medium (357.7–493.2)                                    | 20               | 31             | 0.57     | 0.57 (0.24–1.32)      |
| High (>493.2)   | 20               | 25             | 0.46     | 0.40 (0.17–0.96)      |
| <i>P</i> for trend                                      |                  |                |          | 0.037                 |

<sup>a</sup> Adjusted for age, age at first intercourse, marital status, cigarette smoking status, race, and BMI.

<sup>b</sup>  $n = 169$ .

<sup>c</sup>  $n = 170$ .

trients and HPV persistence. No association was observed between HPV persistence and circulating folate levels. After adjustment, circulating vitamin B<sub>12</sub> concentrations remained inversely associated with HPV persistence ( $P$  for trend, 0.037). Women with circulating levels in the highest tertile (>493.2 pg/ml) of vitamin B<sub>12</sub> were significantly less likely to have a persistent infection (OR = 0.4; 95% CI = 0.17–0.96).

## Discussion

Infection with persistent oncogenic HPV infection is the major risk factor for the development of cervical dysplasia (5, 6, 10, 11). In previous studies, folate, carotenoids, vitamin C, vitamin E, and retinols have been investigated as potential modifiers of cervical dysplasia and cancer risk (12). The current study, however, is the first conducted to examine the association of nutrients involved in DNA methylation (*i.e.*, folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, and methionine) and risk of HPV persistence. The findings from this investigation suggest that circulating vitamin B<sub>12</sub> concentrations may be protective against HPV persistence. However, no significant reduction in HPV persistence risk was observed for dietary intake of folate, vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, methionine from food alone, and food and supplements combined or for circulating concentrations of folate.

Most investigations of diet and cervical neoplasia have used a retrospective design and, therefore, were unable to measure HPV persistence. To our knowledge, no study has previously addressed the association between vitamin B<sub>12</sub> and HPV persistence, although two previous studies have assessed circulating vitamin B<sub>12</sub> concentrations in the prevention of cervical dysplasia (28) or cancer (30). Goodman *et al.* (28) reported no association between circulating vitamin B<sub>12</sub> concentrations and atypical squamous cells of undetermined significance and low-grade or high-grade squamous intraepithelial lesions. Differences in study findings may be because of dissimilarities in the racial distributions of cohorts, a factor known to influence food choices. In a nested case control study, no association was observed between serum vitamin B<sub>12</sub> concentrations and carcinoma *in situ* or invasive cervical cancer (28). However, this study assessed HPV-16 antibody status at baseline only and, therefore, could not assess other oncogenic HPV types.

In our population, high circulating vitamin B<sub>12</sub> concentrations were protective against HPV persistence. One hypothesized mechanism by which vitamin B<sub>12</sub> may protect against cervical carcinogenesis is through viral DNA methylation.

DNA methylation plays a significant role in gene expression, DNA structural stability, and DNA damage and repair mechanisms (16, 41), all of which are believed to be important in preventing carcinogenesis. A randomized trial examining the effect of supplemental folate (42), a methyl donor nutrient, among participants with colon adenomas reported that folate supplementation increased genomic methylation, suggesting that higher dietary consumption of certain nutrients may be protective through their influence on gene methylation status. In support of this hypothesis, a decrease in *in vitro* HPV transcription has been shown when the regulatory upstream region was methylated (13, 14), suggesting a role for methylation in preventing the maintenance of HPV infection.

It is also possible that circulating vitamin B<sub>12</sub> is a surrogate marker for some other unmeasured factor that is protective against HPV persistence. In our study, circulating vitamin B<sub>12</sub> concentrations and dietary intake measures were poorly correlated, which is consistent with a previous report from a similar population (43). These poor correlations suggest that diet and circulating concentrations measure different exposures and may help to explain why a relationship between circulating vitamin B<sub>12</sub> concentrations, but not dietary vitamin B<sub>12</sub> intake, was observed in this study.

There are several strengths to consider when interpreting the results of this study. HPV status was determined with multiple measures of HPV infection over a 9-month period. This study measured both dietary intake and circulating measures of folate and vitamin B<sub>12</sub>, within the same woman. The database used to calculate folate nutrient values from the AFFQ was established to account for the addition of fortified grain products to the American diet, as determined by the completion date of the AFFQ.

As well, potential limitations need to be considered when interpreting the results from this study. Only 346 of women invited to the follow-up visits participated, thus limiting the power to detect statistically significant differences between groups. Because this study was conducted at only one clinic site, the results may not be generalizable to other populations. Although we were not able to assess type-specific oncogenic infections because of the molecular method used to detect HPV, the risk of cervical dysplasia has been shown to increase with either the same or different type oncogenic HPV persistence (6). Therefore, HPV persistence with an oncogenic type, as determined in our study, provides a useful measure of subsequent cervical neoplasia risk. As with any study, assessing the dietary intake of folate is problematic as the dietary intake database is limited because of the difficulties of analytically quantifying food folate content (44). Errors in the USDA nutrient database for folate (45) may have resulted in misclassification of dietary folate status leading to bias toward the null value. Such bias may explain why a protective association between dietary folate intake from food sources and HPV persistence was not observed. Similarly, RBC folate is a more precise measure of long-term circulating folate levels, whereas serum and plasma are more variable based on recent dietary intake (46). Although RBC folate was not assessed, the influence of participants' most recent meal on circulating folate concentrations was minimized by collecting blood samples from fasting participants.

In conclusion, results from this study indicate that elevated circulating levels of vitamin B<sub>12</sub> reduce the risk of HPV persistence. Although these findings suggest a role for vitamin B<sub>12</sub> in preventing cervical carcinogenic events, larger studies using multiple measures over time need to be conducted to further investigate this relationship.

## References

- Parkin, D. M., Pisani, P., and Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. *Int. J. Cancer*, 80: 827–841, 1999.
- Franco, E. L. Epidemiology of anogenital warts and cancer. *Obstet. Gynecol. Clin. North Am.*, 23: 597–623, 1996.
- Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J. Pathol.*, 189: 12–19, 1999.
- Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. *J. Natl. Cancer Inst. (Bethesda)*, 87: 796–802, 1995.
- Ho, G. Y., Burk, R. D., Klein, S., Kadish, A. S., Chang, C. J., Palan, P., Basu, J., Tachezy, R., Lewis, R., and Romney, S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. *J. Natl. Cancer Inst. (Bethesda)*, 87: 1365–1371, 1995.
- Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., and Burk, R. D. Natural history of cervicovaginal papillomavirus infection in young women. *N. Engl. J. Med.*, 338: 423–428, 1998.
- Ho, G. Y., Palan, P. R., Basu, J., Romney, S. L., Kadish, A. S., Mikhail, M., Wassertheil-Smolter, S., Runowicz, C., and Burk, R. D. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. *Int. J. Cancer*, 78: 594–599, 1998.
- Wheeler, C. M., Greer, C. E., Becker, T. M., Hunt, W. C., Anderson, S. M., and Manos, M. M. Short-term fluctuations in the detection of cervical human papillomavirus DNA. *Obstet. Gynecol.*, 88: 261–268, 1996.
- Moscicki, A. B., Palefsky, J., Smith, G., Siboshki, S., and Schoolnik, G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. *Obstet. Gynecol.*, 82: 578–585, 1993.
- Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. *N. Engl. J. Med.*, 327: 1272–1278, 1992.
- Moscicki, A. B., Hills, N., Shiboski, S., Powell, K., Jay, N., Hanson, E., Miller, S., Clayton, L., Farhat, S., Broering, J., Darragh, T., and Palefsky, J. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. *JAMA*, 285: 2995–3002, 2001.
- Potischman, N., and Brinton, L. A. Nutrition and cervical neoplasia. *Cancer Causes Control*, 7: 113–126, 1996.
- Rosl, F., and Schwarz, E. Regulation of E6 and E7 oncogenic transcription. In: M. Tommasino (ed.), *Papillomaviruses in Human Cancer: Role of E6 and E7 Oncoproteins*, pp. 25–70. Austin, Texas: Landes Bioscience and Chapman & Hall, 1997.
- Rosl, F., Arab, A., Klevenz, B., and zur Hausen, H. The effect of DNA methylation on gene regulation of human papillomaviruses. *J. Gen. Virol.*, 74: 791–801, 1993.
- Bailey, L. B., and Gregory, J. F., III. Folate metabolism and requirements. *J. Nutr.*, 129: 779–782, 1999.
- Choi, S. W., and Mason, J. B. Folate and carcinogenesis: an integrated scheme. *J. Nutr.*, 130: 129–132, 2000.
- Selhub, J., and Miller, J. W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. *Am. J. Clin. Nutr.*, 55: 131–138, 1992.
- VanEenwyk, J., Davis, F. G., and Colman, N. Folate, vitamin C, and cervical intraepithelial neoplasia. *Cancer Epidemiol. Biomarkers Prev.*, 1: 119–124, 1992.
- Liu, T., Soong, S. J., Wilson, N. P., Craig, C. B., Cole, P., Macaluso, M., and Butterworth, C. E., Jr. A case control study of nutritional factors and cervical dysplasia. *Cancer Epidemiol. Biomarkers Prev.*, 2: 525–530, 1993.
- Kanetsky, P. A., Gammon, M. D., Mandelblatt, J., Zhang, Z. F., Ramsey, E., Dnistrian, A., Norkus, E. P., and Wright, T. C., Jr. Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. *Nutr. Cancer*, 31: 31–40, 1998.
- Wideroff, L., Potischman, N., Glass, A. G., Greer, C. E., Manos, M. M., Scott, D. R., Burk, R. D., Sherman, M. E., Wacholder, S., and Schiffman, M. A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix. *Nutr. Cancer*, 30: 130–136, 1998.
- Ziegler, R. G., Jones, C. J., Brinton, L. A., Norman, S. A., Mallin, K., Levine, R. S., Lehman, H. F., Hamman, R. F., Trumble, A. C., Rosenthal, J. F., et al. Diet and the risk of *in situ* cervical cancer among white women in the United States. *Cancer Causes Control*, 2: 17–29, 1991.
- Brock, K. E., Berry, G., Mock, P. A., MacLennan, R., Truswell, A. S., and Brinton, L. A. Nutrients in diet and plasma and risk of *in situ* cervical cancer. *J. Natl. Cancer Inst. (Bethesda)*, 80: 580–585, 1988.

24. Ziegler, R. G., Brinton, L. A., Hamman, R. F., Lehman, H. F., Levine, R. S., Mallin, K., Norman, S. A., Rosenthal, J. F., Trumble, A. C., and Hoover, R. N. Diet and the risk of invasive cervical cancer among white women in the United States. *Am. J. Epidemiol.*, *132*: 432–445, 1990.
25. Verreault, R., Chu, J., Mandelson, M., and Shy, K. A case-control study of diet and invasive cervical cancer. *Int. J. Cancer*, *43*: 1050–1054, 1989.
26. Herrero, R., Potischman, N., Brinton, L. A., Reeves, W. C., Brenes, M. M., Tenorio, F., de Britton, R. C., and Gaitan, E. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicators. *Am. J. Epidemiol.*, *134*: 1335–1346, 1991.
27. Kwasniewska, A., Tukendorf, A., and Semczuk, M. Folate deficiency and cervical intraepithelial neoplasia. *Eur. J. Gynaecol. Oncol.*, *18*: 526–530, 1997.
28. Goodman, M. T., McDuffie, K., Hernandez, B., Wilkens, L. R., and Selhub, J. Case-control study of plasma folate, homocysteine, vitamin B<sub>12</sub>, and cysteine as markers of cervical dysplasia. *Cancer (Phila.)*, *89*: 376–382, 2000.
29. Butterworth, C. E., Jr., Hatch, K. D., Macaluso, M., Cole, P., Sauberlich, H. E., Soong, S. J., Borst, M., and Baker, V. V. Folate deficiency and cervical dysplasia. *JAMA*, *267*: 528–533, 1992.
30. Alberg, A. J., Selhub, J., Shah, K. V., Viscidi, R. P., Comstock, G. W., and Helzlsouer, K. J. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B<sub>12</sub>, and homocysteine. *Cancer Epidemiol. Biomarkers Prev.*, *9*: 761–764, 2000.
31. Weinstein, S. J., Ziegler, R. G., Frongillo, E. A., Jr., Colman, N., Sauberlich, H. E., Brinton, L. A., Hamman, R. F., Levine, R. S., Mallin, K., Stolley, P. D., and Bisogni, C. A. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U. S. women. *J. Nutr.*, *131*: 2040–2048, 2001.
32. Potischman, N., Brinton, L. A., Laiming, V. A., Reeves, W. C., Brenes, M. M., Herrero, R., Tenorio, F., de Britton, R. C., and Gaitan, E. A case-control study of serum folate levels and invasive cervical cancer. *Cancer Res.*, *51*: 4785–4789, 1991.
33. Butterworth, C. E., Jr., Hatch, K. D., Gore, H., Mueller, H., and Krumdieck, C. L. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. *Am. J. Clin. Nutr.*, *35*: 73–82, 1982.
34. Butterworth, C. E., Jr., Hatch, K. D., Soong, S. J., Cole, P., Tamura, T., Sauberlich, H. E., Borst, M., Macaluso, M., and Baker, V. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. *Am. J. Obstet. Gynecol.*, *166*: 803–809, 1992.
35. Childers, J. M., Chu, J., Voigt, L. F., Feigl, P., Tamimi, H. K., Franklin, E. W., Alberts, D. S., and Meyskens, F. L., Jr. Chemoprevention of cervical cancer with folic acid: a phase III southwest oncology group intergroup study. *Cancer Epidemiol. Biomarkers Prev.*, *4*: 155–159, 1995.
36. Lorincz, A. T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens. *Papillomavirus Rep.*, *7*: 1–5, 1996.
37. Block, G., Hartman, A. M., Dresser, C. M., Carroll, M. D., Gannon, J., and Gardner, L. A data-based approach to diet questionnaire design and testing. *Am. J. Epidemiol.*, *124*: 453–469, 1986.
38. Thomson, C. A., Giuliano, A. R., Graver, E., Hartz, V., Whitacre, R., Pierce, J., and Marshall, J. R. Reproducibility and validity of the Arizona Cancer Center food frequency questionnaire (AFFQ) among WHEL cohort participants. 25<sup>th</sup> Annual ASPO Meeting, New York, New York, 2001.
39. Martinez, M. E., Marshall, J. R., Graver, E., Whitacre, R. C., Woolf, K., Ritenbaugh, C., and Alberts, D. S. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. *Cancer Epidemiol. Biomarkers Prev.*, *8*: 941–946, 1999.
40. Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. *Federal Register*, *61*: 8781–8797, 1996.
41. Kim, Y. I. Folate and carcinogenesis: evidence, mechanisms, and implications. *J. Nutr. Biochem.*, *10*: 66–88, 1999.
42. Kim, Y. I., Baik, H. W., Fawaz, K., Knox, T., Lee, Y. M., Norton, R., Libby, E., and Mason, J. B. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. *Am. J. Gastroenterol.*, *96*: 184–195, 2001.
43. Green, T. J., Allen, O. B., and O'Connor, D. L. A three-day weighed food record and a semiquantitative food-frequency questionnaire are valid measures for assessing the folate and vitamin B-12 intakes of women aged 16 to 19 years. *J. Nutr.*, *128*: 1665–1671, 1998.
44. Subar, A. F., Block, G., and James, L. D. Folate intake and food sources in the U. S. population. *Am. J. Clin. Nutr.*, *50*: 508–516, 1989.
45. Gregory, J. F., III. Case study: folate bioavailability. *J. Nutr.*, *131* (4 Suppl.): 1376S–1382S, 2001.
46. Senti, F. R., and Pilch, S. M. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). *J. Nutr.*, *115*: 1398–1402, 1985.

# Cancer Epidemiology, Biomarkers & Prevention

AACR American Association  
for Cancer Research

## Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women

Rebecca L. Sedjo, Paula Inserra, Martha Abrahamsen, et al.

*Cancer Epidemiol Biomarkers Prev* 2002;11:353-359.

**Updated version** Access the most recent version of this article at:  
<http://cebp.aacrjournals.org/content/11/4/353>

**Cited articles** This article cites 42 articles, 14 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/11/4/353.full#ref-list-1>

**Citing articles** This article has been cited by 4 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/11/4/353.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/11/4/353>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.